On May 15, 2025, Iovance Biotherapeutics, Inc., a biotech firm specializing in polyclonal tumor infiltrating lymphocyte therapies for cancer patients, disclosed the approval of inducement stock options. A total of 278,770 shares of the company’s common stock were granted to 59 new non-executive employees on this date.